This Solution Provider Webinar is brought to you by DIA in cooperation with

As drug development becomes more complex and personalized, traditional randomized controlled trials (RCTs) are no longer sufficient to answer every research question—particularly in rare diseases, and situations lacking head-to-head comparisons. Regulators, payers and other stakeholders are increasingly turning to real-world evidence (RWE) to address the gaps, but concerns around data quality, fit-for-purpose study design, and regulatory acceptance remain. This webinar will explore the challenges of using real-world data (RWD) in observational studies, and show how life sciences teams are leveraging automation and AI to accelerate development timelines, reduce burden on sites and patients, and generate high-quality, regulatory-ready insights. Learn how these innovations are unlocking more efficient, scalable, and fit-for-purpose approaches to evidence generation.